Yin Zhipeng, Li Hao, Zhao Heng, Bentum-Ennin Lutterodt, Xia Yang, Wang Zaibiao, Hu Wanglai, Gu Hao, Zhang Shangxin, Li Guangyun
Department of Gastrointestinal Surgery, The People's Hospital of Bozhou, The Affiliated Bozhou Hospital of Anhui Medical University, Bozhou, China.
Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Heliyon. 2024 Aug 10;10(16):e36133. doi: 10.1016/j.heliyon.2024.e36133. eCollection 2024 Aug 30.
Mutations in oncogenes such as , and promote the growth and survival of tumors, while excessive RAS/RAF/MEK/ERK activation inhibits tumor growth. In this study we examined the precise regulatory machinery that maintains a moderate RAS/RAF/MEK/ERK pathway activation during CRC. Here, using bioinformatic analysis, transcriptomic profiling, gene silencing and cellular assays we discovered that a circular RNA, circRAPGEF5, is significantly upregulated in KRAS mutant colorectal cancer (CRC) cells. CircRAPGEF5 suppressed mutant and constitutively activated KRAS and the expression of the death receptor TNFRSF10A. Silencing of circRAPGEF5-induced RAS/RAF/MEK/ERK signaling hyperactivation and apoptosis in CRC cells suggesting that an upregulation of circRAPEF5 may suppress the expression of TNFRSF10A and aid CRC progression by preventing apoptosis, while the direct interactions between circRAPGEF5 and elements of the RAS/RAF/MEK/ERK pathway was not identified, which nevertheless can be the basis for future research. Moreover, EIF4A3, was observed to share a similar expression pattern with circRAPEF5 and demonstrated to be a major controller of circRAPGEF5 via the promotion of circRAPGEF5 circularization and its silencing reduced circRAPGEF5 levels. Taken together, our findings reveal a mechanism of accurate RAS/RAF/MEK/ERK signaling regulation during CRC progression maintained by upregulation of circRAPGEF5 which may be a plausible target for future clinical applications that seek to induce CRC cell apoptosis via the RAS/RAF/MEK/ERK signaling pathway.
诸如 、 和 等癌基因的突变会促进肿瘤的生长和存活,而过度的RAS/RAF/MEK/ERK激活则会抑制肿瘤生长。在本研究中,我们研究了在结直肠癌(CRC)过程中维持适度RAS/RAF/MEK/ERK信号通路激活的精确调控机制。在此,我们通过生物信息学分析、转录组分析、基因沉默和细胞实验发现,一种环状RNA,即circRAPGEF5,在KRAS突变型结直肠癌细胞中显著上调。CircRAPGEF5抑制突变型和组成型激活的KRAS以及死亡受体TNFRSF10A的表达。沉默circRAPGEF5会诱导CRC细胞中的RAS/RAF/MEK/ERK信号超激活和细胞凋亡,这表明circRAPEF5的上调可能通过防止细胞凋亡来抑制TNFRSF10A的表达并促进CRC进展,虽然未确定circRAPGEF5与RAS/RAF/MEK/ERK通路元件之间的直接相互作用,但这仍可为未来研究提供基础。此外,观察到EIF4A3与circRAPEF5具有相似的表达模式,并被证明是circRAPGEF5的主要调控因子,它通过促进circRAPGEF5环化来实现这一点,其沉默会降低circRAPGEF5水平。综上所述,我们的研究结果揭示了CRC进展过程中精确的RAS/RAF/MEK/ERK信号调控机制,该机制通过circRAPGEF5的上调得以维持,这可能是未来临床应用中寻求通过RAS/RAF/MEK/ERK信号通路诱导CRC细胞凋亡的一个合理靶点。